News Article

Global MedTech and diagnostocs leader GE HealthCare has acquired Sofie Biosciences, a privately-held developer of radiopharmaceuticals and molecular imaging diagnostics, in a transaction valued at $945 million.

The deal marks a major step forward in GE HealthCare’s strategy to expand its precision diagnostics business and secure greater operational control over the highly complex and time-sensitive radiopharmaceutical supply chain. Molecular imaging is one of the fastest-growing fields in medical diagnostics, and this acquisition directly addresses the rising demand for highly targeted clinical imaging agents.

Sofie Biosciences specialises in developing and manufacturing next-generation positron emission tomography imaging drugs, particularly those targeting fibroblast activation protein, which is highly expressed in many solid tumours. These advanced imaging agents allow clinicians to detect and monitor cancers with unprecedented precision.

By integrating Sofie’s diagnostic pipeline and its established manufacturing network into its existing pharmaceutical diagnostics division, GE HealthCare is positioning itself as a vertically integrated leader in the theranostics market. The acquisition is expected to enhance GE HealthCare’s ability to supply crucial imaging agents to healthcare facilities across both North America and Europe, where regulatory approvals for new tracers are accelerating.

For healthcare operators and investors, this $945m transaction underscores the intense strategic interest in molecular imaging and the broader radiopharmaceutical landscape. The production of diagnostic radiopharmaceuticals requires rapid, localised manufacturing due to the short half-life of radioactive isotopes, making physical infrastructure and specialised manufacturing sites a major competitive barrier.

Through this acquisition, GE HealthCare secures a robust network of radiopharmacies and manufacturing facilities. This vertical integration not only protects GE HealthCare from potential supply chain bottlenecks but also enhances its competitive position against rivals like Siemens Healthineers and Philips, who are also expanding their oncology and molecular imaging portfolios.